Article Text

Download PDFPDF

2022-RA-1547-ESGO Primary Leiomyosarcoma of female genital tract: Salah Azaiez institute experience
Free
  1. Saida Sakhri,
  2. Takoua Chalouati,
  3. Malek Bouhani,
  4. Amani Jellali,
  5. Hanen Bouaziz and
  6. Khaled Rahal
  1. Surgical oncology department, Salah Azaiez institute, Tunis, Tunisia

Abstract

Introduction/Background Leiomyosarcomas of the gynecological tract (LMS) are heterogeneous group of mesenchymal gynecological cancers with unspecific but dismal prognosis since they generally spread even in early stages.

Methodology We conducted a retrospective study of all female with LMS treated at our institution during the previous 22 years. Clinicopathological information, therapies, and results were all documented.

Results Data were collected from 16 women. The median age at diagnosis was 51 years old (31–77 yo). 50% of patients were menopausal. Bleeding was the most common symptom, followed by pelvic discomfort. Ten patients had uterine leiomyosarcoma, three had cervix leiomyosarcoma, and three had vaginal leiomyosarcoma. The average size of the tumor was 6.4 cm (3–10 cm). There were no evidence of distant metastasis in all patients. As an initial treatment, fifteen patients had surgery, while one patient received extemal beam radiation followed by brachytherapy. Adjuvant chemotherapy was administered to four patients, while adjuvant radiation was administered to seven. Six patients were diagnosed with LMS grade 1, three with grade 2, and seven with grade 3. The average duration of follow-up was 61 months. Full remission was obtained in nine cases while five suffered from a progressive disease course and two had locoregional recurrence. Seven patients died.

Conclusion The relative rarity of LMS, as well as its clinical variety, inhibit studies aiming at improving understanding of the disease and makes establishing the best therapy challenging.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.